MiR-182 Is Associated with Growth, Migration and Invasion in Prostate Cancer via Suppression of FOXO1.

Background: MicroRNA (miRNA) have been shown to regulate gene expression in many cancers. MiR-182 has recently been found to be prognostic for patients treated with radical prostatectomy for prostate cancer. We sought to assess miR-182 as a prognostic marker and understand its role in prostate cancer progression and metastasis.

MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR).

MicroRNAs (miRNAs) are single-stranded, 18-24 nucleotide long, non-coding RNA molecules. They are involved in virtually every cellular process including development, apoptosis, and cell cycle regulation. MiRNAs are estimated to regulate the expression of 30% to 90% of human genes by binding to their target messenger RNAs (mRNAs).

miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer.

Expression profiling studies using microarrays and other methods have shown that microRNAs (miRNAs) are dysregulated in a wide variety of human cancers. The up-regulation of miR-221 has been reported in carcinomas of the pancreas, breast, and papillary thyroid, as well as in glioblastoma and chronic lymphocytic leukaemia. In prostate cancer, however, down-regulation of miR-221 has been repeatedly confirmed in miRNA expression studies.